GANX

#4050
Gain Therapeutics, Inc. - Common Stock
1.7 7 USD
-0.02%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
1.77
1.79
Intervallo Annuale
1.53
4.34
Variazione giornaliera
-1.67%
Variazione Mensile
+5.99%
Variazione di 6 mesi
-31.92%
Variazione Annuale
-7.81%
Chiusura Precedente
1.8 0
Open
1.7 9
Minimo
1.7 7
Massimo
1.7 9
Volume
63
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Gain Therapeutics, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Gain Therapeutics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Gain Therapeutics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Gain Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Gain Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Gain Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Gain Therapeutics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Gain Therapeutics, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Gain Therapeutics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Gain Therapeutics, Inc. current report, Q1 FY2026
8-K

Gain Therapeutics, Inc. current report, Q1 FY2025

Full document

Business Context and Reporting Period

This Form 8-K Current Report was filed by Gain Therapeutics, Inc. (GANX) on January 7, 2025, covering events occurring on January 6, 2025. The filing primarily addresses significant changes in executive leadership and the associated compensatory arrangements.

Key Financial Metrics

This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on personnel appointments and employment terms.

Material Changes

  • CEO Appointment: Gene Mack was appointed President and Chief Executive Officer (CEO) and a member of the Board of Directors, effective January 6, 2025. He previously served as CFO (since April 2024) and interim CEO (since June 2024).
  • CFO Appointment: Gianluca Fuggetta was appointed Senior Vice President, Finance, and Principal Financial Officer, effective January 6, 2025, succeeding Mr. Mack.
  • Compensation Adjustments: New employment agreements were executed for both executives with updated salary and equity terms.

Guidance, Outlook, and Management Commentary

The filing contains no forward-looking guidance, financial outlook, or management commentary regarding business strategy or risks. It details the specific terms of the new employment agreements:

  • Gene Mack (CEO):
    • Annual base salary: $500,000.
    • Target annual incentive bonus: 50% of base salary.
    • Equity: Granted an option to purchase 271,325 shares at $2.44/share (25% vesting at year one, remainder monthly over three years). Eligible for an additional performance-based option for up to 271,325 shares.
    • Severance: One year of base salary and COBRA coverage upon termination without Cause or for Good Reason. In a Change of Control, severance extends to 18 months with full acceleration of unvested equity.
  • Gianluca Fuggetta (CFO):
    • Annual base salary: CHF 200,000.
    • Target annual incentive bonus: 30% of base salary.

Investor Verification Checklist

  • Verify the terms of the First Amended and Restated Employment Agreement for Gene Mack (Exhibit 10.1).
  • Review the press release dated January 7, 2025 (Exhibit 99.1) for additional context on the leadership transition.
  • Confirm the vesting schedule and performance criteria for the additional equity grants mentioned for Mr. Mack.
  • Monitor future filings for the appointment of a new Chief Financial Officer if Mr. Fuggetta's role is interim or if further restructuring occurs.

Notizie